T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Due to treatments that frequently block the estrogen receptor, several patients with breast cancer experience a change in hormonal status and a significant decrease in quality of life. Wiley discusses a study that examined between 57 and 112 women with breast cancer receiving biomemetic bio-identical hormone replacement therapy.

Results showed that these patients experienced a higher quality of life, Wiley says, mentioning a patient with triple-negative breast cancer who has been on the therapy for 10 years.